Clinical trial · Observational
Delineation of Target Volume of Stereotactic Radiotherapy for Spinal Tumors
NCT06587022CI-TRIAL-00080667ST-SBRTrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study was to compare efficacy and side effects of two target delineation methods for stereotactic radiotherapy of metastatic spinal tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Spinal Tumor | Spinal Cord Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Target volume delineation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- group 1
- description
- Group 1(small target delineation)：The target bolume only includes local tumor.
- interventionNames
- Radiation: Target volume delineation
- label
- group 2
- description
- Group 2(small target delineation)：The target bolume includes local tumor and adjacent vertebral area.
- interventionNames
- Radiation: Target volume delineation
Primary outcomes (2)
- measure
- Disease Control Rate（DCR）
- timeFrame
- 2 years
- description
- Disease Control Rate（DCR），including complete response（CR），partial response(PR) and stable disease(SD ).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with spinal metastases or primary tumors receiving stereotactic radiotherapy; * Patients with sufficent pre-treatment imaging data * Patients who can cooperate with imaging review and follow-up after radiotherapy. Exclusion Criteria: * Patients with an expected survival of less than 3 months; * Patients with second-course radiotherapy; * Patients with physical conditions that cannot tolerate stereotactic radiotherapy; * Patients with extensive spinal metastasis and no local therapeutic value
References
Publications (0)
Data not yet available
No reference posted for this study.